The Department of Health and Human Services recently canceled $500 million in funding for vaccine research that it had previously pledged to scientists.

Obviously, the broken promise is a disappointment for those researchers. It also sends a mixed signal to America’s biotech industry, particularly to the small- and mid-size firms that drive a disproportionate share of medical innovation and job creation, that government support for innovative medicines may no longer be reliable. That may, unfortunately, push the innovative companies that have made the United States the global leader in life sciences to take their talent, capital and jobs elsewhere.

HHS’s decision is opposed to the administration’s efforts to support small businesses, foster innovation and spur economic growth.

Multinati

See Full Page